Home / Companies / Aclaris Therapeutics, Inc. / 5 Jun 2025
Aclaris Therapeutics, Inc.: meeting of 5 Jun 2025
Votes reported on Form N-PX, item by item
110 Form N-PX filers reported votes at the Aclaris Therapeutics, Inc. meeting of 5 Jun 2025. Their records fall into 5 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 69.1% of reported votes for; 18 filers withheld from or voted against at least one nominee.
123 vote records from 32 filers. 5 of the 32 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
135 vote records from 109 filers. 48 of the 104 filers that marked the item either way voted against management. 5 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
41 vote records from 32 filers. 1 of the 32 filers that marked the item either way voted against management.
CAPITAL STRUCTUREIssuer
CAPITAL STRUCTURE: management items
Management items in this category are shown together; filers word and number them differently.
41 vote records from 32 filers. 2 of the 32 filers that marked the item either way voted against management.
COMPENSATIONIssuer
COMPENSATION: management items
Management items in this category are shown together; filers word and number them differently.
42 vote records from 32 filers. 11 of the 32 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | Against * | For |
| Fidelity | For | For | For |
| Dimensional | Abstain or withhold * | Against * | For |
| State Street and SPDR | For | For | For |
| Invesco | For | Against * | For |
| Equitable | For | Against * | For |
| Charles Schwab | For | For | For |
| John Hancock and Manulife | For | Against * | For |
| Morgan Stanley, Eaton Vance and Calvert | No report | Against * | No report |
| Goldman Sachs | For | For | For |
| PGIM and Prudential | Abstain or withhold * | Against * | For |
| Jackson National funds | Abstain or withhold * | Against * | For |
| Northern Trust and FlexShares | No report | Against * | No report |
| T. Rowe Price | For | Against * | For |
| Russell Investments | No report | For | No report |
| Victory Capital | For | Against * | For |
| BNY Mellon | No report | For | No report |
| Pacific Life funds | For | For | For |
| Federated Hermes | No report | For | No report |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Aclaris Therapeutics, Inc. meeting?
110 Form N-PX filers reported votes at the meeting of 5 Jun 2025. On say-on-pay, 48 of 104 voted against management (46.2%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Aclaris Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Aclaris Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Aclaris Therapeutics, Inc. with a meeting date within three days of 5 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.